title: Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
abstract: BACKGROUND
  The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published clinical practice guidelines which include recommendations for management of anaemia in established renal failure.
  
  
  OBJECTIVE
  To determine the extent to which the guidelines for anaemia management are met in the UK.
  
  
  METHODS
  Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2010.
  
  
  RESULTS
  In the UK, in 2010 53.6% of patients commenced dialysis therapy with Hb ≥ 10.0 g/dl (median Hb 10.1 g/dl). The median Hb of haemodialysis (HD) patients was 11.5 g/dl with an interquartile range (IQR) of 10.5-12.3 g/dl. Of HD patients 84.6% had Hb ≥ 10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.6 g/dl (IQR 10.6-12.5 g/dl). Of UK PD patients, 87.2% had Hb ≥ 10.0 g/dl. The median ferritin in HD patients in EWNI was 444 µg/L (IQR 299-635) and 96% of HD patients had a ferritin ≥ 100 µg/L. The median ferritin in PD patients was 264 µg/L (IQR 148-426) with 86% of PD patients having a ferritin ≥ 100 µg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,020 vs. 6,202 IU/week).
  
  
  CONCLUSIONS
  Of prevalent HD patients, 52.7% had Hb ≥ 10 and ≤ 12 g/dl. Of prevalent PD patients, 54.3% had Hb 10.5-12.5 g/dl.
authors.affiliation: UK Renal Registry, Bristol, UK.
authors.forename: Lynsey
authors.initials: L
authors.lastname: Webb
authors.forename: Julie
authors.initials: J
authors.lastname: Gilg
authors.forename: Martin
authors.initials: M
authors.lastname: Wilkie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D002391:Catchment Area, Health; D015331:Cohort Studies; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D005293:Ferritins / Q000097:blood*; D019983:Guideline Adherence; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use; D006436:Hemodialysis Units, Hospital / Q000706:statistics & numerical data; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D015995:Prevalence; D012042:Registries / Q000706:statistics & numerical data*; D006435:Renal Dialysis / Q000009:adverse effects / Q000592:standards / Q000706:statistics & numerical data*; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin; D005293:Ferritins